Low-power AMI (active medical implants) firms fight to retain waveband
This article was originally published in Clinica
Manufacturers of ultra-low power active medical implants (ULP-AMIs) are having to fight to keep the frequency band at which their instruments have traditionally worked. National frequency regulators in Europe are challenging implant manufacturers' rights to use 9-315 kHz, arguing that this waveband could be subject to interference that could harm patients and others users of the frequency.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.